Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease
NCT ID: NCT03331926
Last Updated: 2020-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
199 participants
OBSERVATIONAL
2017-01-01
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Injectable Collagenase and Percutaneous Needle Fasciotomy for Dupuytren's Contracture
NCT01538017
Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)
NCT01229436
Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF
NCT02647619
Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture
NCT01226121
Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease
NCT03000114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xiapex
Follow-up of effect of treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* xiapex treatment
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jeppe Lange
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeppe Lange
Research secretary
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charlotte Hartig-Andreasen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Regionshospitalet Horsens
References
Explore related publications, articles, or registry entries linked to this study.
Hartig-Andreasen C, Schroll L, Lange J. Clostridium histolyticum as first-line treatment of Dupuytren's disease. Dan Med J. 2019 Feb;66(2):A5527.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XIAPEX FOLLOWUP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.